Trial Profile
A Phase II Study of Ibrutinib Plus Rituximab Followed by Venetoclax and Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma: Window II Protocol
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Mar 2023
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Cytarabine (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Doxorubicin (Primary) ; Ibrutinib (Primary) ; Methotrexate (Primary) ; Rituximab (Primary) ; Venetoclax (Primary) ; Vincristine (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- Acronyms Window II
- 07 Mar 2023 Planned End Date changed from 22 May 2023 to 22 May 2025.
- 07 Mar 2023 Planned primary completion date changed from 22 Apr 2023 to 22 May 2025.
- 13 Dec 2022 Planned End Date changed from 22 May 2022 to 22 May 2023.